NIHR whitepaper claims UK needs High Throughput Centres after Brexit

pharmafile | October 8, 2018 | News story | Sales and Marketing NHS, NIHR, UK, clinical trials, phase III 

The National Institute for Health Research (NIHR) has released a new whitepaper outlining the substantial benefits NHS High Throughput Centres could bring to UK patients and the NHS.

The policy paper argues that the establishment of High Throughput Centres will be vital in making Britain competitive after Brexit.

The Centres, which would be focused towards facilitating late Phase II and Phase III trials, have the potential to make the UK the country of choice for clinical research and attract investment from overseas, while also improving patient outcomes and increasing cost efficiency.

Primarily the Centres would allow patients access to the very latest medical developments through rapid access to clinical trials, while allowing for better care through quicker adoption of innovative treatments and technologies.

“By focusing on collaboration between the clinical research industry and the NHS we can harmonise and improve the clinical research process for both patients and the industry; ultimately working to get new treatments available for patients in a more efficient, but equally robust, way,” explained Jonathan Sheffield, CEO of the NIHR Clinical Research Network.

“The NIHR is actively working to facilitate partnerships between Industry and the NHS; the introduction of High Throughput Centres would extend the work we’ve already begun and accelerate the process to the advantage of those requiring new treatments, as well as the industry.”

Commercially the clinical research industry is worth an estimated £115 billion around the globe each year. Meanwhile the Centres could save the NHS millions of pounds.

“High Throughput Centres just make sense for the international clinical research industry as well as for the U.K. specifically,” said Jacqueline Johnson North, CEO and co-founder of IAOCR who have published the whitepaper.

“The industry, working collaboratively with the NHS, could improve the NHS patient journey with increased awareness and improved availability of clinical trials that could accelerate treatment options and ultimately patient outcomes. Furthermore, they could re-establish the benchmark the industry works to; with an emphasis on the competency of those conducting the research and an accountability to work in the most effective, efficient way; putting the U.K. at the centre of the international clinical research business.”

Louis Goss

Related Content

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …

Latest content